Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : TPT0201
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Tetra Pharm Technologies
Deal Size : Undisclosed
Deal Type : Collaboration
Tetra Pharm and Glysious Partner to Develop Transdermal Endocannabinoid System Drugs
Details : The collaboration aims to revolutionize transdermal release of difficult-to-formulate compounds, including TPT0201, studied for mild cognitive impairment, targeting the endocannabinoid system.
Brand Name : TPT0201
Molecule Type : Undisclosed
Upfront Cash : Undisclosed
April 24, 2024
Lead Product(s) : TPT0201
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Tetra Pharm Technologies
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?